ライフサイエンスコーパス: insulin-like growth factor 1

1 cts regarding leukemia inhibitory factor and insulin-like growth factor 1.

2 model assessment of insulin resistance, and insulin-like growth factor 1.

3 pinal cord, and normalization of circulating insulin-like growth factor 1.

4 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.

5 of growth factors such as interleukin-6 and insulin-like growth factor-1.

6 ccumulation, which was confirmed in vitro as insulin-like growth factor-1, a known mediator of physio

7 Insulin-like growth factor 1 activated the phosphoinosit

8 High values of insulin-like growth factor 1 activation module were asso

9 ve/HER2-negative tumors (interaction between insulin-like growth factor 1 and ER: P = .002; FDR, 0.03

10 Serum levels of both insulin-like growth factor 1 and osteocalcin also were d

11 n kinase, mammalian target of rapamycin, and insulin-like growth factor 1 and their roles regulating

12 RNA expression, but it was increased by both insulin-like growth factor-1 and high, but not low, dose

13 ignificantly influence circulating levels of insulin-like growth factor-1 and insulin-like growth fac

14 ained only a modest amount of variability in insulin-like growth factor-1 and insulin-like growth fac

15 tress syndrome were strongly associated with insulin-like growth factor-1 and insulin-like growth fac

16 Total insulin-like growth factor-1 and insulin-like growth fac

17 tary restriction, which reduces the level of insulin-like growth factor-1 and of other growth factors

18 There was an acute decrease in insulin-like growth factor-1 and unexpectedly myostatin,

19 oligomers, chronic oxidative stress, reduced insulin-like growth factor 1, and astrocytic mediated-Ab

20 reased hippocampal levels of neurotrophin 3, insulin-like growth factor 1, and nerve growth factor an

21 proteinases, and leukemia inhibitory factor, insulin-like growth factor 1, and pentraxin 3, 3 predict

22 ence of transforming growth factor beta1 and insulin-like growth factor 1, and this effect was reduce

23 e MM cell growth conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal ce

24 absorption, stimulation of the secretion of insulin-like growth factor-1, and enhancement of lean bo

25 ocardial vascular endothelial growth factor, insulin-like growth factor-1, and hepatocyte growth fact

26 ecies associated with inflammation, insulin, insulin-like growth factor-1, and sirtuins.

27 d expression of colony stimulating factor-1, insulin-like growth factor-1, and vascular endothelial g

28 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co

29 deficiencies in growth hormone signaling and insulin-like growth factor-1 are strongly associated wit

30 m levels of nonfasting glucose, insulin, and insulin-like growth factor-1 as well as high levels of g

31 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros

32 data suggest that an altered growth hormone/insulin-like growth factor 1 axis, which may be common t

33 The growth hormone-insulin-like growth factor-1 axis plays a role in normal

34 ich was amplified by MCL-specific cytokines (insulin-like growth factor-1, B-cell activating factor,

35 ctivated by tonic treatment with insulin and insulin-like growth factor-1 but not by depolarization a

36 sCLU expression was stimulated by insulin-like growth factor-1, but suppressed by p53.

37 Insulin-like growth factor-1 did not recover in those wh

38 as well as four long-lived mutants (insulin/insulin-like growth factor-1, dietary restriction, prote

39 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo

40 sociates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) axis.

41 growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

42 entified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) pathway as well

43 Additionally, the blood levels of insulin-like growth factor-1, hepatocyte growth factor,

44 Insulin like growth factor-1 (IGF-1) stimulates increase

45 Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mecasermi

46 To determine the roles of insulin and insulin-like growth factor 1 (IGF-1) action in adipose t

47 L-17 mRNA levels, enhanced the expression of insulin-like growth factor 1 (IGF-1) and IL-10 and stimu

48 ere associated with plasma concentrations of insulin-like growth factor 1 (IGF-1) and insulin-like gr

49 egulate activity-dependent molecules such as insulin-like growth factor 1 (IGF-1) and interleukin-1be

50 Furthermore, cerebellar levels of insulin-like growth factor 1 (IGF-1) are high during lig

51 ric dysfunction (EED) and disturbance of the insulin-like growth factor 1 (IGF-1) axis.

52 us polymorphisms lie within HtrA1's putative insulin-like growth factor 1 (IGF-1) binding domain.

53 In breast carcinomas, increased levels of insulin-like growth factor 1 (IGF-1) can act as a mitoge

54 igitumumab, an anticancer drug that prevents insulin-like growth factor 1 (IGF-1) from binding to its

55 Circulating insulin-like growth factor 1 (IGF-1) has been shown to a

56 ciation between blood lead levels (BLLs) and insulin-like growth factor 1 (IGF-1) has not been charac

57 Low levels of insulin-like growth factor 1 (IGF-1) have been observed

58 Insulin and insulin-like growth factor 1 (IGF-1) have important role

59 rowth delay is associated with low levels of insulin-like growth factor 1 (IGF-1) in a mouse model of

60 The objective is to investigate the role of insulin-like growth factor 1 (IGF-1) in the regulation o

61 Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid

62 We recently found that insulin-like growth factor 1 (IGF-1) is a key mediator o

63 Insulin-like Growth Factor 1 (IGF-1) is associated with

64 Insulin-like growth factor 1 (IGF-1) is known to have di

65 mones and neuropeptides, such as insulin and insulin-like growth factor 1 (IGF-1) likely modulate gly

66 spective case-control studies suggested that insulin-like growth factor 1 (IGF-1) or insulin-like gro

67 Insulin and insulin-like growth factor 1 (IGF-1) receptor signaling

68 marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inh

69 ed signaling networks, including the insulin/insulin-like growth factor 1 (IGF-1) signaling cascade a

70 ly attenuated by a deficiency in the insulin/insulin-like growth factor 1 (IGF-1) signaling in C. ele

71 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,

72 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.

73 Insulin-like growth factor 1 (IGF-1) stimulates cartilag

74 Insulin-like growth factor 1 (IGF-1) stimulates myoblast

75 liferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows GH rele

76 f the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce osteoclas

77 Akt, activated by insulin-like growth factor 1 (IGF-1) treatment in neonat

78 Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5

79 glial fibrillary acidic protein (GFAP), and insulin-like growth factor 1 (IGF-1) were analyzed 12 ho

80 anismal level as shown by down-regulation of insulin-like growth factor 1 (IGF-1), a hallmark of prem

81 Serum levels of insulin-like growth factor 1 (IGF-1), a hormone with kno

82 pe 2 diabetes mellitus (T2DM) via binding of insulin-like growth factor 1 (IGF-1), an insulin-like ho

83 CF patients have low levels of insulin-like growth factor 1 (IGF-1), and our prior stud

84 ile groups) of circulating concentrations of insulin-like growth factor 1 (IGF-1), insulin-like growt

85 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt

86 Insulin-like growth factor 1 (IGF-1), the most abundant

87 schistosome-infected pregnancies, including insulin-like growth factor 1 (IGF-1), tumor growth facto

88 In addition, insulin-like growth factor 1 (IGF-1)-induced cell migrat

89 We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond

90 acetylation region of Rictor exhibit reduced insulin-like growth factor 1 (IGF-1)-stimulated mTORC2 k

91 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).

92 ress osteopontin (OPN) and receptors for the insulin-like growth factor 1 (IGF-1).

93 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).

94 n-associated cytokines, macrophages released insulin-like growth factor 1 (IGF-1).

95 +DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-I) and its binding pro

96 art, by an over 50% reduction in glucose and insulin-like growth factor 1 (IGF-I) levels.

97 We found that stimulation of insulin-like growth factor-1 (IGF-1) and IGF-1R protein

98 In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated

99 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the

100 Insulin-like growth factor-1 (IGF-1) and signal transduc

101 recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-

102 e investigated the effects of overexpressing insulin-like growth factor-1 (IGF-1) as a potential ther

103 expression and phosphorylation, counteracted insulin-like growth factor-1 (IGF-1) binding to CLL cell

104 ts stimulatory effects primarily mediated by insulin-like growth factor-1 (IGF-1) both systemically a

105 ed that increased expression of IL-1beta and insulin-like growth factor-1 (IGF-1) coincided with indu

106 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm

107 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.

108 Our earlier studies showed that insulin-like growth factor-1 (IGF-1) increases collagen

109 us, we expected autophagy to be activated by insulin-like growth factor-1 (IGF-1) inhibition, which c

110 Insulin-like growth factor-1 (IGF-1) is associated with

111 Exogenous Insulin-Like Growth Factor-1 (IGF-1) is neuroprotective

112 Insulin-like growth factor-1 (IGF-1) levels were signifi

113 -beta3) with varying release kinetics and/or insulin-like growth factor-1 (IGF-1) on osteochondral ti

114 eurons, have triggered a renewed interest in insulin-like growth factor-1 (IGF-1) pathway activation

115 Insulin, growth hormone (GH), and insulin-like growth factor-1 (IGF-1) play key roles in t

116 e MC4R, we assessed pulsatile GH release and insulin-like growth factor-1 (IGF-1) production and/or r

117 Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si

118 of adult rabbit extraocular muscle (EOM) to insulin-like growth factor-1 (IGF-1) results in signific

119 In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o

120 The Src family kinases (SFK) and insulin-like growth factor-1 (IGF-1) signaling axes are

121 Insulin-like growth factor-1 (IGF-1) signaling is import

122 atory pathway for E2F-2 production involving insulin-like growth factor-1 (IGF-1) signaling is simult

123 -kinase (PI3K) that functions in the insulin/insulin-like growth factor-1 (IGF-1) signaling pathway.

124 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.

125 ells secrete a subthreshold concentration of insulin-like growth factor-1 (IGF-1) that primes the IGF

126 Insulin-like growth factor-1 (IGF-1), a small protein/po

127 In this study, insulin-like growth factor-1 (IGF-1), an important growt

128 When cells were stimulated with insulin-like growth factor-1 (IGF-1), an increased inter

129 poor phagocytosis, reduced up-regulation of insulin-like growth factor-1 (IGF-1), and impaired muscl

130 ysiological declines in growth hormone (GH), insulin-like growth factor-1 (IGF-1), and sex steroids.

131 ascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1), haemodynamic chang

132 Insulin-like growth factor-1 (IGF-1), insulin, and IL-6

133 ce (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and adipon

134 ated with endothelin (ET-1), norepinephrine, insulin-like growth factor-1 (IGF-1), or isoproterenol a

135 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG

136 motility was regulated by norepinephrine and insulin-like growth factor-1 (IGF-1), which increased or

137 by neutralizing antibodies directed against insulin-like growth factor-1 (IGF-1).

138 ansforming growth factor-beta (TGF-beta) and insulin-like growth factor-1 (IGF-1).

139 resistance leading to low concentrations of insulin-like growth factor-1 (IGF-1); relative hypercort

140 n epidermal growth factor receptor (HER) and insulin-like growth factor-1 (IGF-1R) family of receptor

141 growth hormone concentration >2.5 mug/L and insulin-like growth factor 1 [IGF-1] concentration >1.3

142 Whether the growth hormone (GH)/insulin-like growth factor 1(IGF-1) axis exerts cardiopr

143 is characterized by a marked decrease in the insulin-like growth factor 1 (IGF1) and IGF1 receptor (I

144 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN

145 Insulin-like growth factor 1 (IGF1) and phosphoinositol

146 Concentrations of insulin-like growth factor 1 (IGF1) and vascular endothe

147 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of

148 ain-derived neurotrophic factor that affects insulin-like growth factor 1 (IGF1) expression in Mecp2(

149 Insulin-like growth factor 1 (IGF1) has potent trophic e

150 novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.

151 at phorbol ester 12-myristate 13-acetate and insulin-like growth factor 1 (IGF1) induced rod differen

152 Insulin-like growth factor 1 (IGF1) induces skeletal mus

153 osensor for the determination of the hormone insulin-like growth factor 1 (IGF1) is reported for the

154 Insulin-like growth factor 1 (IGF1) is secreted in an au

155 receptor tyrosine kinases by neuregulin and insulin-like growth factor 1 (IGF1) leads to the phospho

156 ed that mouse strains with lower circulating insulin-like growth factor 1 (IGF1) level at 6 mo have s

157 enuation through low growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels.

158 EVIEW: To summarize the recent evidence that insulin-like growth factor 1 (IGF1) mediates growth effe

159 Insulin-like growth factor 1 (IGF1) mediates the growth-

160 Insulin-like growth factor 1 (IGF1) promotes a physiolog

161 Signaling through the insulin-like growth factor 1 (IGF1) receptor by locally

162 ic species with high binding affinity to the insulin-like growth factor 1 (IGF1) receptor.

163 es indicate that insulin receptors (IRs) and insulin-like growth factor 1 (IGF1) receptors (IGF1Rs) c

164 ression caused reduced fat stores, pituitary insulin-like growth factor 1 (IGF1) resistance, and a de

165 Integrin alphavbeta3 plays a role in insulin-like growth factor 1 (IGF1) signaling (integrin-

166 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo

167 toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and preve

168 epithelium fate by regulating apoptosis and insulin-like growth factor 1 (IGF1) signaling.

169 kes through alterations in Ca(2+), cAMP, and insulin-like growth factor 1 (IGF1) signaling.

170 ing to a pronounced reduction in circulating insulin-like growth factor 1 (IGF1), and ASO-10-27 treat

171 ytosis-related genes, including Mmp9, Mmp12, insulin-like growth factor 1 (Igf1), and Glycoprotein (t

172 Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto

173 reased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in grow

174 or muscle growth, including the induction of insulin-like growth factor 1 (IGF1), as well as concomit

175 d preadipocytes to differentiation inducers [insulin-like growth factor 1 (IGF1), glucocorticoid, and

176 ulin growth factor (IGF) signaling including insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1

177 ted sites cluster on the binding surfaces of insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1

178 of the receptors of growth hormone (GH) and insulin-like growth factor 1 (IGF1).

179 HANK3 expression or by treating neurons with insulin-like growth factor 1 (IGF1).

180 ctions as well as growth effects mediated by insulin-like growth factor 1 (IGF1).

181 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic

182 oxo1, a key downstream signaling molecule of insulin-like growth factor 1 (IGF1)/insulin actions, reg

183 When insulin-like growth factor-1 (IGF1) binds to its recepto

184 Insulin-like growth factor-1 (IGF1) is a major therapeut

185 Here, we show that insulin-like growth factor-1 (IGF1) levels are reduced i

186 ical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elici

187 ion and proliferation as well as insulin and insulin-like growth factor-1 (IGF1) receptor activation

188 Integrin alphavbeta3 plays a role in insulin-like growth factor-1 (IGF1) signaling (integrin-

189 eration, the expression of cellular insulin, insulin-like growth factor-1 (IGF1), and GHRH receptor,

190 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).

191 well as the neuronal and myotrophic factor, insulin-like growth factor-1 (IGF1).

192 secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).

193 , and Fox transcriptional targets (p21, p27, insulin-like growth factor 1 [IGF1]) also were examined.

194 cer pinpoint to a potential new function for insulin-like growth factor 1 (Igf1r) in the basal epithe

195 ng, with selectivity over the related kinase insulin-like growth factor-1 (IGF1R).

196 Hormones such as leptin, ghrelin, insulin-like growth factor 1, IGFBP3, and cytokines, inc

197 Drugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were

198 factors transforming growth factor beta1 and insulin-like growth factor 1 in the chronically inflamed

199 es activated by growth hormone, insulin, and insulin-like growth factor-1 in mammals and their orthol

200 zation of the conserved longevity regulator, insulin-like growth factor-1, in the marrow microenviron

201 nel of serologic testing that included serum insulin-like growth factor-1, insulin-like growth factor

202 growth factor-1 systemically pointed to the insulin-like growth factor-1-insulin-like growth factor-

203 rs in 12q23 (P = 9.69 x 10(-10)) where IGF1 (insulin-like growth factor 1) is located.

204 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero

205 eased expression of pro-regenerative factors insulin-like growth factor 1, leukemia inhibitory factor

206 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l

207 In addition, we found lower insulin-like growth factor 1 levels in F508del Cftr(tm1E

208 Evaluation III was strongly associated with insulin-like growth factor-1 levels; and age was strongl

209 ntial circulating modulators of muscle mass--insulin-like growth factor-1, myostatin, and growth and

210 Circulating insulin-like growth factor-1, myostatin, and growth and

211 gus serum as well as novel therapies such as insulin-like growth factor 1, neuropeptides and acupunct

212 and fibrin extracellular matrix proteins and insulin-like growth factor 1 on the force production of

213 TRPC6 complementation and by treatment with insulin-like growth factor-1 or hyperforin, a TRPC6-spec

214 -1 and AKT following stimulation by insulin, insulin-like growth factor-1, or the neurotrophins (NGF

215 n Index scores correlated significantly with insulin-like growth factor-1 (P < 0.03) and insulin-like

216 Supplementation of insulin-like growth factor 1 partially reverted the DR-i

217 The insulin-like growth factor-1 pathway was activated to a

218 egulate distinct signaling events in insulin/insulin-like growth factor 1 pathways.

219 ation but instead sustained signaling of the insulin-like growth factor 1/phosphatidylinositol 3-kina

220 a3(L122P) mice displayed an 80% reduction in insulin-like growth factor 1, postnatal growth retardati

221 nclude mammalian target of rapamycin, c-MET, insulin like growth factor 1 receptor and cytotoxic T-ly

222 However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron

223 the insulin receptor (F-IRKO) or both IR and insulin-like growth factor 1 receptor (F-IR/IGFRKO).

224 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter

225 he closely related receptor tyrosine kinases insulin-like growth factor 1 receptor (IGF-1R) and insul

226 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c

227 Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls

228 The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been

229 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane

230 We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca

231 Expression of insulin-like growth factor 1 receptor (IGF-1R), an upstr

232 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub

233 cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific

234 TEN) homolog expression and induction of the insulin-like growth factor 1 receptor (IGF-1R).

235 e mitogenic and antiapoptotic signaling from insulin-like growth factor 1 receptor (IGF-IR), insulin

236 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation

237 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as

238 ciated with increased phosphorylation of the insulin-like growth factor 1 receptor (IGF1R), which is

239 s determined that LMP1 selectively activates insulin-like growth factor 1 receptor (IGF1R).

240 ang et al that describes a critical role for insulin-like growth factor 1 receptor in the progression

241 human IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor in thymic epitheli

242 The perinuclear insulin-like growth factor 1 receptor pool connects extr

243 elegans, the highly conserved DAF-2/insulin/insulin-like growth factor 1 receptor signaling (IIS) pa

244 tion of the Gap 2/mitosis transition and the insulin-like growth factor 1 receptor signaling cascade

245 alized response is achieved by activation of insulin-like growth factor 1 receptor signaling complexe

246 s as an autocrine activator of the beta-cell insulin-like growth factor 1 receptor signaling pathway.

247 2 (Cyclin D2), CCND1 (Cyclin D1), and IGF1R (insulin-like growth factor 1 receptor) genes involved in

248 LY294002) signaling, but not an inhibitor of insulin-like growth factor 1 receptor, abrogated TrkC-me

249 nd downregulation of the activities of Rac1, insulin-like growth factor 1 receptor, protein kinase B,

250 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h

251 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.

252 apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.

253 rgistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR.

254 actor (PlGF), induces the phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) and the i

255 Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine

256 In the present study, we report that insulin-like growth factor-1 receptor (Igf-1r) gene expr

257 Increased expression or signaling from the insulin-like growth factor-1 receptor (IGF-1R) has been

258 ls activates tyrosine phosphorylation of the insulin-like growth factor-1 receptor (IGF-1R) in a time

259 abolished these effects of insulin, whereas insulin-like growth factor-1 receptor (IGF-1R) silencing

260 ifferentiation induction is dependent on the insulin-like growth factor-1 receptor (IGF-1R) survival-

261 beta-Arrestin1 is also recruited to the insulin-like growth factor-1 receptor (IGF-1R), a recept

262 nockdown by RNAi decreased expression of the insulin-like growth factor-1 receptor (IGF-1R), resultin

263 ntibody (immunoglobulin G1 subclass) against insulin-like growth factor-1 receptor (IGF-1R).

264 ortic smooth muscle cell (SMC) expression of insulin-like growth factor-1 receptor (IGF-1R).

265 For instance, insulin-like growth factor-1 receptor (IGF1R) antibodies

266 The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are highly

267 Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in cli

268 The receptor tyrosine kinase (RTK) insulin-like growth factor-1 receptor (IGF1R) is implica

269 he purpose of this study was to characterize insulin-like growth factor-1 receptor (IGF1R) protein ex

270 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).

271 P-REX1 also promoted insulin-like growth factor-1 receptor activation, sugges

272 lomerase axis, population-doubling time, and insulin-like growth factor-1 receptor expression in CSCs

273 e, telomere length, telomerase activity, and insulin-like growth factor-1 receptor expression were me

274 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically

275 ated fibroblast growth factor receptor-3 and insulin-like growth factor-1 receptor, and in coronary v

276 ulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor.

277 ns and endogenously expressed stathmin-1 and insulin-like growth factor-1 receptor.

278 oantigens including thyrotropin receptor and insulin-like growth factor-1 receptor.

279 differences in the expression pattern of the insulin-like growth factor-1 receptor/mammalian target o

280 nique sequence changes in growth hormone and insulin-like growth factor 1 receptors are also observed

281 s, together with a high circulating level of insulin-like growth factor-1, represent a novel biomarke

282 Treatment with recombinant human insulin-like growth factor-1 restores responses of PV(+)

283 with increased 17beta-estradiol but not with insulin-like growth factor 1 serum levels in miglustat-t

284 cking platform transduces the insulin/IGF-1 (insulin like growth factor 1) signal to intracellular ef

285 LNK attenuated insulin-like growth factor 1 signaling by inhibition of

286 Insulin-like growth factor 1 signaling involved in cell

287 ate 1 (IRS1), a component of the insulin and insulin-like growth factor 1 signaling pathway.

288 cts primarily by blunting the growth hormone/insulin-like growth factor-1 signaling pathway in liver.

289 Adaptor proteins in the insulin/insulin-like-growth factor-1 signaling pathways, such as

290 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

291 Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu

292 growth factor, hepatocyte growth factor, and insulin-like growth factor-1, stimulating angiogenesis.

293 The high concentration of insulin-like growth factor-1 systemically pointed to the

294 We report here that insulin-like growth factor 1 triggers a fast and indepen

295 luding a proliferation-induced ligand, BAFF, insulin-like growth factor 1, vascular endothelial growt

296 ingulate, treatment-related changes in serum insulin-like growth factor 1 were positively correlated

297 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated

298 growth factor, hepatocyte growth factor, and insulin-like growth factor 1 when transplanted into the

299 yotube hypertrophy through the expression of insulin-like growth factor 1, which is dependent on Galp

300 This potentiation is produced by insulin-like growth factor-1, whose binding proteins are